Abstract
It has been shown that the hallucinogenic potencies of LSD, the phenylisopropylamines, such as DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) and DOI (4-iodo-2,5-dimethoxyphenylisopropylamine), and the indoleaklylamines, such as DMT (dimethyltryptamine) and 5-OMe-DMT (5-methoxy-dimethyltryptamine), strongly correlate with their in vitro 5-HT2 receptor binding affinities in rat cortical homogenates. In order to ascertain if this correlation applies to human 5-HT2 receptors as well, we examined the affinities of 13 psychoactive compounds at 3H-ketanserin-labelled 5-HT2 receptors in human cortical samples. Both radioligand binding and autoradiographical procedures were used. As in rat brain d-LSD was the most potent displacer of 3H-ketanserin specific binding with a K i of 0.9 nM. The phenylisopropylamine DOI also displayed high affinity (K i of 6 nM). Stereospecific interactions were found with DOB; (-_ DOB had a K i of 17 nM while (+) DOB had a K i of 55 nM. The behaviorally active compound DOM (4-methyl-2,5-phenylisopropylamine) had an affinity of 162 nM while its behaviorally less active congener iso-DOM had an affinity of 6299 nM. The indolealkylamines 5-OMe-DMT and DMT competed with moderate affinities (207 and 462 nM, respectively). In general, Hill coefficients were significantly less than unity which is consistent with an agonist interaction with 5-HT2 receptors. MDMA, a substituted amphetamine analog was inactive with a K i of greater than 10 μM. A strong correlation was found for the hallucinogen affinities and human hallucinogenic potencies (r=0.97). Also, human and rat brain 5-HT2 receptor affinities were strongly correlated (r=0.99). These results strongly support the hypothesis that the hallucinogenic effects of these drugs in humans are mediated in whole or in part via 5-HT2 receptors. Furthermore, these studies imply that treatment with 5-HT2 receptor antagonists may be effective in reversing the hallucinogenic effects caused by the ingestion, of LSD and LSD-like drugs.
Similar content being viewed by others
References
Battaglia G, Shannon M, Bordundvaag B, Titeler M (1983) Properties of 3H-prazosin-labelled alpha-1 receptors in rat brain and porcine neurointermediate lobe. J Neurochem 41:538–542
Glennon RA, Young R, Rosecrans JA, Anderson GM (1982) Discriminative stimulus properties of MDA analogs Biol Psychiatry 17:807–814
Glennon RA, Young R, Rosecrans JA (1983) Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol 91:189–196
Glennon RA, Rosecrans JA, Young R (1984a) Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev 3:289–376
Glennon RA, Titeler M, McKenney JD (1984b) Evidence for 5-HT2 receptor involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2205–2211
Glennon RA, Seggel MR, Soine WH, Herrick-Davis K, Lyon RA, Titeler M (1988) 125I-1-(2,5-Dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high affinity state of 5-HT2 serotonin receptors. J Med Chem 31:5–7
Hoyer D, Karpf A (1988) 125I-SCH 23982, a “selective” D1 receptor antagonist labels with high affinity 5-HT1C sites in pig choroid plexus. Eur J Pharmacol 150:181–184
Leysen JE, Eens A, Gommeren W, Gompel PV, Wynants J, Janssen PAJ (1987) Nonserotonergic 3H-ketanserin binding sites in striatal membranes are associated with a dopac release system on dopaminergic nerve endings. Eur J Pharmacol 134:373–375
Lyon RA, Glennon RA, Titeler M (1986) 3,4-Methylenedioxy-methamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 88:525–526
Lyon RA, Davis KH, Titeler M (1987) 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide sensitive state of cortical 5-HT2 receptors. Mol Pharmacol 31:194–199
Lyon RA, Titeler M, Seggel MR, Glennon RA (1988) Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens. Eur J Pharmacol 145:291–297
McPherson GA (1983) A practical computer-based approach to the analysis of radioligand binding experiments Comput Programs Biomed 17:107–114
Rasmussen K, Aghajanian GK (1986) Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists. Brain Res 385:395–400
Shannon M, Battaglia G, Glennon RA, Titeler M (1984) 5-HT1 and 5-HT2 binding properties of the hallucinogen 1-(2,5-dimethoxyphenyl)2-aminopropane (2,5 DMA). Eur J Pharmacol 102:23–29
Shulgin A (1978) Psychotomimetic drugs: structure-activity relationships. In: Iversen LL, Iversen S, Snyder S (eds) Handbook of psychopharmacology. Plenum Press, New York
Titeler M, Herrick K, Lyon RA, McKenney JD, Glennon RA (1985) 3H-DOB: a specific agonist radioligand for 5-HT2 serotonin receptors. Eur J Pharmacol 117:145–146
Titeler M, Lyon RA, Glennon RA (1988) Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94:213–216
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sadzot, B., Baraban, J.M., Glennon, R.A. et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology 98, 495–499 (1989). https://doi.org/10.1007/BF00441948
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00441948